新生儿解脲支原体感染的临床药物治疗进展

蔡辈博; 陈菲菲; 罗芳

doi:10.7499/j.issn.1008-8830.2503019

PDF(598 KB)

HTML

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (10) : 1286-1290. DOI: 10.7499/j.issn.1008-8830.2503019

综述

新生儿解脲支原体感染的临床药物治疗进展

蔡辈博 (综述) ,
陈菲菲 ,
罗芳 (审校)

作者信息 +

Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection

Author information +

文章历史 +

摘要

解脲支原体（Ureaplasma urealyticum, UU）是新生儿呼吸道定植或感染的常见病原体，可通过母婴垂直传播，且不受胎膜早破时间及分娩方式的影响。UU感染是引起新生儿早产和低出生体重等的重要因素，并与支气管肺发育不良及神经发育障碍等不良结局密切相关。由于新生儿免疫系统及器官发育尚未成熟，药物治疗需兼顾有效性及安全性。目前，新生儿UU感染的治疗方案尚无统一标准。该文综述了新生儿UU感染的药物治疗方案，旨在为临床治疗提供参考。

Abstract

Ureaplasma urealyticum (UU) is a common pathogen colonizing or infecting the neonatal respiratory tract. It can be vertically transmitted from mother to infant, irrespective of the duration of premature rupture of membranes and the mode of delivery. UU infection is an important factor contributing to preterm birth and low birth weight and is closely associated with adverse outcomes such as bronchopulmonary dysplasia and neurodevelopmental impairment. Given the immaturity of neonatal immune and organ systems, pharmacologic treatment must balance efficacy and safety. Currently, no unified standard regimen has been established for the treatment of neonatal UU infection. This review summarizes pharmacotherapeutic options for neonatal UU infection to inform clinical practice.

导出引用

蔡辈博, 陈菲菲, 罗芳. 新生儿解脲支原体感染的临床药物治疗进展[J]. 中国当代儿科杂志. 2025, 27(10): 1286-1290 https://doi.org/10.7499/j.issn.1008-8830.2503019

Bei-Bo CAI, Fei-Fei CHEN, Fang LUO. Advances in clinical pharmacotherapy for neonatal Ureaplasma urealyticum infection[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(10): 1286-1290 https://doi.org/10.7499/j.issn.1008-8830.2503019

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

[1]

Tadera

, Kitagawa

, Kitano

, et al. Prevalence of Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum detection in urine and respiratory tract samples in Hiroshima, Japan[J]. Heliyon, 2023, 9(3): e14543. PMCID: PMC10036642. DOI: 10.1016/j.heliyon.2023.e14543 .

https://www.ncbi.nlm.nih.gov/pubmed/36967949

本文引用 [1]

[2]	石永言, 富建华. 解脲脲原体感染与新生儿疾病[J]. 中华实用儿科临床杂志, 2021, 36(14): 1059-1062. DOI: 10.3760/cma.j.cn101070-20201222-01929 . 本文引用 [1]

[3]	Ma J, Wang Z, Luo C, et al. Epidemiological and clinical characteristics of neonatal Ureaplasma urealyticum infection[J]. Infect Drug Resist, 2024, 17: 1323-1332. PMCID: PMC10995099. DOI: 10.2147/IDR.S452014 . https://www.ncbi.nlm.nih.gov/pubmed/38585416 本文引用 [1]

[4]	Silwedel C, Laube M, Speer CP, et al. The role of Ureaplasma species in prenatal and postnatal morbidity of preterm infants: current concepts[J]. Neonatology, 2024, 121(5): 627-635. DOI: 10.1159/000539613 . https://www.ncbi.nlm.nih.gov/pubmed/38934167 本文引用 [1]

[5]	魏红玲, 邢燕, 周颖, 等. 胎龄小于32周早产儿解脲脲原体肺炎的临床特征分析[J]. 中华预防医学杂志, 2021, 55(2): 239-244. DOI: 10.3760/cma.j.cn112150-20201208-01432 . https://www.ncbi.nlm.nih.gov/pubmed/34645186 本文引用 [1]

[6]	郑淮武, 万胜明, 邱素清. 解脲支原体与新生儿疾病关系的研究进展[J]. 中华新生儿科杂志（中英文）, 2019, 34(3): 234-238. DOI: 10.3760/cma.j.issn.2096-2932.2019.03.019 . 本文引用 [2]

[7]

Jonduo

, Vallely

, Wand

, et al. Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis[J]. BMJ Open, 2022, 12(8): e062990. PMCID: PMC9422885. DOI: 10.1136/bmjopen-2022-062990 .

https://www.ncbi.nlm.nih.gov/pubmed/36028274

本文引用 [1]

[8]	陈凌, 汤颖, 杨羡球. 解脲脲原体感染新生儿血常规、D-二聚体及降钙素原水平与坏死性小肠结肠炎的关系研究[J]. 中国现代医学杂志, 2024, 34(15): 7-12. DOI: 10.3969/j.issn.1005-8982.2024.15.002 .

[9]	Sprong KE, Mabenge M, Wright CA, et al. Ureaplasma species and preterm birth: current perspectives[J]. Crit Rev Microbiol, 2020, 46(2): 169-181. DOI: 10.1080/1040841X.2020.1736986 . https://www.ncbi.nlm.nih.gov/pubmed/32141797

[10]

Silwedel

, Schnee

, Liese

, et al. Neonatal central nervous system infection by Ureaplasma species is rare, but relevant: results from a multicenter nationwide surveillance study[J]. Infection, 2025, 53(4): 1329-1339. PMCID: PMC12316750. DOI: 10.1007/s15010-024-02435-2 .

https://www.ncbi.nlm.nih.gov/pubmed/39821739

[11]	王燕琼, 曾雅丽, 陈雪雨, 等. 超早产儿解脲脲原体感染及定植状态的临床特征分析[J]. 中国当代儿科杂志, 2024, 26(8): 811-816. PMCID: PMC11334552. DOI: 10.7499/j.issn.1008-8830.2403002 . https://www.ncbi.nlm.nih.gov/pubmed/39148384

[12]	Sun T, Fu J. Analysis of the clinical features of intrauterine Ureaplasma urealyticum infection in preterm infants: a case-control study[J]. Front Pediatr, 2021, 9: 774150. PMCID: PMC8696116. DOI: 10.3389/fped.2021.774150 . https://www.ncbi.nlm.nih.gov/pubmed/34956983 本文引用 [1]

[13]	Pansieri C, Pandolfini C, Elie V, et al. Ureaplasma, bronchopulmonary dysplasia, and azithromycin in European neonatal intensive care units: a survey[J]. Sci Rep, 2014, 4: 4076. PMCID: PMC5379254. DOI: 10.1038/srep04076 . https://www.ncbi.nlm.nih.gov/pubmed/24518104 本文引用 [1]

[14]

Samra

, Rosenberg

, Dan

. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin[J]. J Chemother, 2011, 23(2): 77-79. DOI: 10.1179/joc.2011.23.2.77 .

https://www.ncbi.nlm.nih.gov/pubmed/21571622

本文引用 [4]

[15]	胡海燕. 新生儿呼吸道解脲支原体的感染情况与药敏分析[J]. 中国卫生检验杂志, 2021, 31(2): 165-167. 本文引用 [1]

[16]

Mabanta

, Pryhuber

, Weinberg

, et al. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum [J]. Cochrane Database Syst Rev, 2003(4): CD003744. DOI: 10.1002/14651858.CD003744 .

https://www.ncbi.nlm.nih.gov/pubmed/14583992

本文引用 [1]

[17]	Resch B, Gutmann C, Reiterer F, et al. Neonatal Ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics[J]. Infection, 2016, 44(3): 323-327. DOI: 10.1007/s15010-015-0858-7 . https://www.ncbi.nlm.nih.gov/pubmed/26518581 本文引用 [1]

[18]

Abdellatif

, Ghozy

, Kamel

, et al. Association between exposure to macrolides and the development of infantile hypertrophic pyloric stenosis: a systematic review and meta-analysis[J]. Eur J Pediatr, 2019, 178(3): 301-314. DOI: 10.1007/s00431-018-3287-7 .

https://www.ncbi.nlm.nih.gov/pubmed/30470884

本文引用 [1]

[19]

Cakan

, Polat

, Kocazeybek

, et al. Assessment of antibiotic susceptibility of Ureaplasma urealyticum from prostitutes and outpatient clinic patients using the E-test and agar dilution method[J]. Chemotherapy, 2003, 49(1/2): 39-43. DOI: 10.1159/000069781 .

https://www.ncbi.nlm.nih.gov/pubmed/12714809

本文引用 [1]

[20]	Viscardi RM, Terrin ML, Magder LS, et al. Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(6): 615-622. PMCID: PMC7592356. DOI: 10.1136/archdischild-2019-318122 . https://www.ncbi.nlm.nih.gov/pubmed/32170033 本文引用 [1]

[21]

Viscardi

, Terrin

, Magder

, et al. Randomized trial of azithromycin to eradicate Ureaplasma respiratory colonization in preterm infants: 2-year outcomes[J]. Pediatr Res, 2022, 91(1): 178-187. PMCID: PMC8413397. DOI: 10.1038/s41390-021-01437-2 .

https://www.ncbi.nlm.nih.gov/pubmed/33658655

本文引用 [1]

[22]	Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study[J]. Respir Res, 2007, 8(1): 41. PMCID: PMC1896160. DOI: 10.1186/1465-9921-8-41 . https://www.ncbi.nlm.nih.gov/pubmed/17550598 本文引用 [1]

[23]

Ballard

, Shook

, Bernard

, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial[J]. Pediatr Pulmonol, 2011, 46(2): 111-118. DOI: 10.1002/ppul.21352 .

https://www.ncbi.nlm.nih.gov/pubmed/20963840

本文引用 [1]

[24]	Gharehbaghi MM, Peirovifar A, Ghojazadeh M, et al. Efficacy of azithromycin for prevention of bronchopulmonary dysplasia (BPD)[J]. Turk J Med Sci, 2012, 42(6): 1070-1075. DOI: 10.3906/sag-1107-18 . 本文引用 [1]

[25]	Nunes CR, Procianoy RS, Corso AL, et al. Use of azithromycin for the prevention of lung injury in mechanically ventilated preterm neonates: a randomized controlled trial[J]. Neonatology, 2020, 117(4): 522-528. DOI: 10.1159/000509462 . https://www.ncbi.nlm.nih.gov/pubmed/32894857 本文引用 [1]

[26]	Zeng Y, Huang Z, Wang Y, et al. Azithromycin for preventing bronchopulmonary dysplasia in extremely preterm infants: a cohort study[J]. Pediatr Pulmonol, 2025, 60(1): e27384. PMCID: PMC11758769. DOI: 10.1002/ppul.27384 . https://www.ncbi.nlm.nih.gov/pubmed/39503175 本文引用 [1]

[27]

Chen

, Huang

, Lin

, et al. Association of Ureaplasma infection pattern and azithromycin treatment effect with bronchopulmonary dysplasia in Ureaplasma positive infants: a cohort study[J]. BMC Pulm Med, 2023, 23(1): 229. PMCID: PMC10294412. DOI: 10.1186/s12890-023-02522-4 .

https://www.ncbi.nlm.nih.gov/pubmed/37365524

本文引用 [1]

[28]	张艳, 宋晓彤, 徐思媛, 等. 红霉素与阿奇霉素治疗早产儿解脲脲原体感染的随机对照研究[J]. 中华新生儿科杂志（中英文）, 2024, 39(12): 723-728. DOI: 10.3760/cma.j.issn.2096-2932.2024.12.004 . 本文引用 [1]

[29]	Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis[J]. Pediatr Pulmonol, 2021, 56(5): 957-966. DOI: 10.1002/ppul.25230 . https://www.ncbi.nlm.nih.gov/pubmed/33382534 本文引用 [1]

[30]

Chang

, Ballard

, Johnson

, et al. Azithromycin for eradication of Ureaplasma and prevention of bronchopulmonary dysplasia in preterm neonates in the neonatal intensive care unit[J]. J Pediatr Pharmacol Ther, 2023, 28(1): 10-19. PMCID: PMC9901312. DOI: 10.5863/1551-6776-28.1.10 .

https://www.ncbi.nlm.nih.gov/pubmed/36777984

本文引用 [1]

[31]	Smith C, Egunsola O, Choonara I, et al. Use and safety of azithromycin in neonates: a systematic review[J]. BMJ Open, 2015, 5(12): e008194. PMCID: PMC4679913. DOI: 10.1136/bmjopen-2015-008194 . https://www.ncbi.nlm.nih.gov/pubmed/26656010 本文引用 [1]

[32]	Ozdemir R, Erdeve O, Dizdar EA, et al. Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants[J]. Pediatrics, 2011, 128(6): e1496-e1501. DOI: 10.1542/peds.2011-1350 . https://www.ncbi.nlm.nih.gov/pubmed/22123897 本文引用 [1]

[33]	Guo D, Cai Y, Chai D, et al. The cardiotoxicity of macrolides: a systematic review[J]. Pharmazie, 2010, 65(9): 631-640. https://www.ncbi.nlm.nih.gov/pubmed/21038838 本文引用 [1]

[34]

Pereyre

, Hénin

, Dolzy

, et al. Evaluation of commercial, customized microdilution plates for Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis antimicrobial susceptibility testing and determination of antimicrobial resistance prevalence in France[J]. J Clin Microbiol, 2024, 62(7): e0022624. PMCID: PMC11324033. DOI: 10.1128/jcm.00226-24 .

https://www.ncbi.nlm.nih.gov/pubmed/38832769

本文引用 [1]

[35]

Yang

, Pan

, Wu

, et al. Antimicrobial resistance in clinical Ureaplasma spp. and Mycoplasma hominis and structural mechanisms underlying quinolone resistance[J]. Antimicrob Agents Chemother, 2020, 64(6): e02560-19. PMCID: PMC7269463. DOI: 10.1128/AAC.02560-19 .

https://www.ncbi.nlm.nih.gov/pubmed/32229497

本文引用 [1]

[36]

Waites

, Crabb

, Xiao

, et al. In vitro activities of eravacycline and other antimicrobial agents against human mycoplasmas and ureaplasmas[J]. Antimicrob Agents Chemother, 2020, 64(8): e00698-20. PMCID: PMC7526834. DOI: 10.1128/AAC.00698-20 .

https://www.ncbi.nlm.nih.gov/pubmed/32513794

本文引用 [1]

[37]	Guo F, Tang Y, Zhang W, et al. DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection[J]. Appl Microbiol Biotechnol, 2022, 106(22): 7643-7659. PMCID: PMC9589543. DOI: 10.1007/s00253-022-12230-4 . https://www.ncbi.nlm.nih.gov/pubmed/36269329 本文引用 [1]

[38]	Fleming D, Patel R. Flurofamide prevention and treatment of Ureaplasma-induced hyperammonemia[J]. Microbiol Spectr, 2022, 10(5): e0192722. PMCID: PMC9602998. DOI: 10.1128/spectrum.01927-22 . https://www.ncbi.nlm.nih.gov/pubmed/35993783 本文引用 [1]

[39]

Biernat-Sudolska

, Rojek-Zakrzewska

, Bilska-Wilkosz

. In-vitro activity of lipoic acid against Ureaplasma urealyticum and Ureaplasma parvum isolated from women with infections of the urogenital tract. A pilot study[J]. Acta Biochim Pol, 2020, 67(4): 623-628. DOI: 10.18388/abp.2020_5413 .

https://www.ncbi.nlm.nih.gov/pubmed/33332062

本文引用 [1]

[40]

Chen

, Zhang

, Zeng

, et al. Subtractive genomics and comparative metabolic pathways profiling revealed novel drug targets in Ureaplasma urealyticum [J]. Front Microbiol, 2024, 15: 1484423. PMCID: PMC11557531. DOI: 10.3389/fmicb.2024.1484423 .

https://www.ncbi.nlm.nih.gov/pubmed/39539704

本文引用 [1]